Abstract:The direct killing of cancer cells by cytotoxic T-lymphocytes (CTL) is critical for achieving effective antitumor immune responses. While several tumor-intrinsic mutations have been identified that promote evasion to CTL killing, there remains a paucity of data cataloging how individual genetic perturbations impact cancer cell fitness under immunotherapeutic selection pressure. Towards this, genetic screens using the CRISPR-Cas9 system have recently been employed, identifying novel intrinsic genetic regulators of cancer immunotherapy fitness. While these initial studies demonstrate the significant potential of unbiased genetic screens for discovery of novel immunotherapy targets, they have been limited in application to a small number of disease models. As such, the degree to which intrinsic genetic perturbations robustly modulate immunotherapy fitness across diverse cancer genotypes remains largely unexplored. To circumvent this knowledge gap, we performed genetic screens across a panel of commonly utilized syngeneic murine cancer cell lines to identify a core set of genes that render cancer cells more sensitive or resistant to CTL killing across diverse genetic backgrounds. An optimized genome-scale gRNA library targeting ~19,000 protein-coding genes in the murine genome (termed mTKO; mouse Toronto Knockout) was created in an analogous manner to our human library. Screens were performed in multiple murine cell lines engineered to express model tumor-associated antigens. Cells were propagated in the presence or absence of preactivated antigen-specific CTLs, and gRNA abundance was quantified by illumina sequencing to identify perturbed genes enriched or depleted in CTL treated versus untreated populations. These screens uncovered known genetic regulators of CTL killing including immune checkpoints (Cd274), antigen presentation machinery (B2m, Tap1/2) and interferon signaling components (Socs1, Jak1/2, Ifngr1/2), benchmarking the utility of this approach. Importantly, we leveraged this dataset to derive a core list of genes whose perturbation significantly modulates cancer-cell fitness to CTL killing across the majority of genotypes screened. Gene set enrichment analysis revealed critical roles for cytokine and TLR signaling, the NF-κB and MAPK pathways as well as the antiviral and antigen presentation machineries. As such, our dataset represents the first step towards a comprehensive understanding of the functional genomic landscape of CTL-mediated cytotoxicity. Citation Format: Keith Lawson, Xiaoyu Zhang, Cris Sousa, Rummy Akthar, Zi Fan, Eiru Kim, Medina Colic, Amy Tong, Katie Chan, Qian Huang, Xiaowei Wang, Kevin Brown, Michael Aregger, Antonio Finelli, Laurie Ailles, Traver Hart, Gillian Kingsbury, Charles Kung, Jason Moffat. Functional genomic landscape of T-cell mediated cytotoxicity [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B60.

Establishment and optimization of genome-wide CRISPR/Cas9-sgRNA screening system in THP1 cell line for functional oncogenes and tumor suppressor genes

Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis

Piggybac Mediates Efficient In Vivo Crispr Library Screening For Tumorigenesis In Mice

Abstract 2634: CRISPR in vivo screen utilizing removable Cas9 system to identify epigenetic immune response modulators in antigen-sensitive mouse syngeneic models

Screening and efficiency verification of CRISPR-Cas9 single-guide RNA against human tumor suppressor gene p53 and PTEN

Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy

CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer

Functional genomic landscape of T-cell mediated cytotoxicity.

Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice

Exposing Cancer with CRISPR-Cas9: from Genetic Identification to Clinical Therapy

High-resolution characterization of gene function using single-cell CRISPR tiling screen

Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library

Advancements in CRISPR Screens for the Development of Cancer Immunotherapy Strategies

CRISPR/Cas9 high-throughput screening in cancer research

Arrayed CRISPR/Cas9 Screening for the Functional Validation of Cancer Genetic Dependencies

CRISPR Screen: a High‐throughput Approach for Cancer Genetic Research

Harnessing the evolving CRISPR/Cas9 for precision oncology

Abstract 3971: Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for anti-tumor drug discovery

CRISPR-mediated Direct Mutation of Cancer Genes in the Mouse Liver.

CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy

CRISPR/Cas9 Screening: Unraveling Cancer Immunotherapy's 'rosetta Stone'.